Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Interpace Biosciences price target lowered to $11 from $12 at H.C. Wainwright » 06:19
06/26/20
06/26
06:19
06/26/20
06:19
IDXG

Interpace Biosciences

$5.44 /

+0.275 (+5.33%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen lowered the firm's price target on Interpace Biosciences to $11 from $12 and reiterates a Buy rating on the shares following the company's Q1 results.

ShowHide Related Items >><<
IDXG Interpace Biosciences
$5.44 /

+0.275 (+5.33%)

IDXG Interpace Biosciences
$5.44 /

+0.275 (+5.33%)

04/23/20 Alliance Global Partners
Interpace Biosciences price target lowered to $9.25 from $21 at Alliance Global
04/23/20 H.C. Wainwright
Interpace Biosciences price target lowered to $12 from $15 at H.C. Wainwright
04/15/20 Janney Montgomery Scott
Interpace Biosciences initiated with a Buy at Janney Montgomery Scott
01/16/20 Oppenheimer
Interpace Biosciences price target raised to $17 from $2 at Oppenheimer
IDXG Interpace Biosciences
$5.44 /

+0.275 (+5.33%)

Earnings
Interpace Biosciences reports Q1 EPS ($2.32), consensus ($1.22) » 17:03
06/25/20
06/25
17:03
06/25/20
17:03
IDXG

Interpace Biosciences

$5.44 /

+0.275 (+5.33%)

Reports Q1 revenue $9.2M,…

Reports Q1 revenue $9.2M, consensus $8.93M. CEO Jack Stover stated, "Q1 revenue was $9.2M and near the top end of our previously announced revenue range. During Q1 we continued to grow our Clinical and Pharma services businesses, however, our Clinical services business was impacted by the pandemic beginning in the second half of March. (...) While we were generally pleased with first quarter progress, we did experience the business impact from the coronavirus pandemic and while recovering, we do anticipate the impact will continue through the remainder of 2020 and perhaps beyond. Our focus for the rest of the year will be continuing to respond to changing conditions while positioning ourselves for growth and expansion, improving business processes and integrating our service offerings."

ShowHide Related Items >><<
IDXG Interpace Biosciences
$5.44 /

+0.275 (+5.33%)

IDXG Interpace Biosciences
$5.44 /

+0.275 (+5.33%)

04/23/20 Alliance Global Partners
Interpace Biosciences price target lowered to $9.25 from $21 at Alliance Global
04/23/20 H.C. Wainwright
Interpace Biosciences price target lowered to $12 from $15 at H.C. Wainwright
04/15/20 Janney Montgomery Scott
Interpace Biosciences initiated with a Buy at Janney Montgomery Scott
01/16/20 Oppenheimer
Interpace Biosciences price target raised to $17 from $2 at Oppenheimer
IDXG Interpace Biosciences
$5.44 /

+0.275 (+5.33%)

Over a month ago
Hot Stocks
Interpace Biosciences subsidiary announces contract with Avalon Healthcare » 06:56
04/27/20
04/27
06:56
04/27/20
06:56
IDXG

Interpace Biosciences

$4.95 /

-1.15 (-18.85%)

Interpace Biosciences…

Interpace Biosciences announced that its subsidiary, Interpace Diagnostics, has entered into a contract with Avalon Healthcare Solutions, a specialty benefit management company. The new contract, whose terms were not disclosed, includes two of the Southeastern U.S.'s largest Blue Cross Blue Shield plans where members can now take advantage of the benefits of ThyGeNEXT and ThyraMIR thyroid testing while reducing their out of pocket expenses due to Interpace's status as an in-network provider. Interpace has successfully achieved positive medical coverage for its services through Medicare as well as other leading national and regional health plans and is now focused on establishing more contracts to optimize the adjudication process.

ShowHide Related Items >><<
IDXG Interpace Biosciences
$4.95 /

-1.15 (-18.85%)

04/23/20 Alliance Global Partners
Interpace Biosciences price target lowered to $9.25 from $21 at Alliance Global
04/23/20 H.C. Wainwright
Interpace Biosciences price target lowered to $12 from $15 at H.C. Wainwright
04/15/20 Janney Montgomery Scott
Interpace Biosciences initiated with a Buy at Janney Montgomery Scott
01/16/20 Oppenheimer
Interpace Biosciences price target raised to $17 from $2 at Oppenheimer
Recommendations
Interpace Biosciences price target lowered to $9.25 from $21 at Alliance Global » 20:10
04/23/20
04/23
20:10
04/23/20
20:10
IDXG

Interpace Biosciences

$6.10 /

+0.045 (+0.74%)

Alliance Global Partners…

Alliance Global Partners analyst Ben Haynor lowered the firm's price target on Interpace Biosciences to $9.25 from reverse-split adjusted $21 but keeps a Buy rating on the shares. The analyst cites the company's below-consensus Q4 revenue as its billings collectors have been unable to collect at historical rates. Haynor adds that despite the sales shortfall, he was encouraged by the diagnostics volume growth, which remained high at ~25% for the year.

ShowHide Related Items >><<
IDXG Interpace Biosciences
$6.10 /

+0.045 (+0.74%)

04/23/20 H.C. Wainwright
Interpace Biosciences price target lowered to $12 from $15 at H.C. Wainwright
04/15/20 Janney Montgomery Scott
Interpace Biosciences initiated with a Buy at Janney Montgomery Scott
01/16/20 Oppenheimer
Interpace Biosciences price target raised to $17 from $2 at Oppenheimer
09/25/19 Oppenheimer
Oppenheimer starts Interpace at Outperform, sees 'clear path to BioPharma'
Recommendations
Interpace Biosciences price target lowered to $12 from $15 at H.C. Wainwright » 07:14
04/23/20
04/23
07:14
04/23/20
07:14
IDXG

Interpace Biosciences

$6.06 /

+0.325 (+5.67%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Yi Chen lowered the firm's price target on Interpace Biosciences to $12 from $15 and reiterates a Buy rating on the shares following the company's sales miss in Q4.

ShowHide Related Items >><<
IDXG Interpace Biosciences
$6.06 /

+0.325 (+5.67%)

04/15/20 Janney Montgomery Scott
Interpace Biosciences initiated with a Buy at Janney Montgomery Scott
01/16/20 Oppenheimer
Interpace Biosciences price target raised to $17 from $2 at Oppenheimer
09/25/19 Oppenheimer
Oppenheimer starts Interpace at Outperform, sees 'clear path to BioPharma'
09/25/19 Oppenheimer
Interpace Diagnostics initiated with an Outperform at Oppenheimer
Earnings
Interpace Biosciences reports Q4 EPS ($2.89), consensus (74c) » 16:09
04/22/20
04/22
16:09
04/22/20
16:09
IDXG

Interpace Biosciences

$6.01 /

+0.28 (+4.89%)

Reports Q4 revenue…

Reports Q4 revenue $4.07M, consensus $10.77M.

ShowHide Related Items >><<
IDXG Interpace Biosciences
$6.01 /

+0.28 (+4.89%)

04/15/20 Janney Montgomery Scott
Interpace Biosciences initiated with a Buy at Janney Montgomery Scott
01/16/20 Oppenheimer
Interpace Biosciences price target raised to $17 from $2 at Oppenheimer
09/25/19 Oppenheimer
Oppenheimer starts Interpace at Outperform, sees 'clear path to BioPharma'
09/25/19 Oppenheimer
Interpace Diagnostics initiated with an Outperform at Oppenheimer
Over a quarter ago
Initiation
Interpace Biosciences initiated with a Buy at Janney Montgomery Scott » 06:16
04/15/20
04/15
06:16
04/15/20
06:16
IDXG

Interpace Biosciences

$4.82 /

+0.01 (+0.21%)

Janney Montgomery Scott…

Janney Montgomery Scott analyst Paul Knight initiated coverage of Interpace Biosciences with a Buy rating.

ShowHide Related Items >><<
IDXG Interpace Biosciences
$4.82 /

+0.01 (+0.21%)

01/16/20 Oppenheimer
Interpace Biosciences price target raised to $17 from $2 at Oppenheimer
09/25/19 Oppenheimer
Oppenheimer starts Interpace at Outperform, sees 'clear path to BioPharma'
09/25/19 Oppenheimer
Interpace Diagnostics initiated with an Outperform at Oppenheimer
Hot Stocks
Interpace Diagnostics announces contract with BCBS of Massachusetts » 06:56
03/10/20
03/10
06:56
03/10/20
06:56
IDXG

Interpace Biosciences

$6.55 /

-0.5 (-7.09%)

Interpace Diagnostics, a…

Interpace Diagnostics, a subsidiary of Interpace Biosciences, announced that it has entered into a contract with Blue Cross Blue Shield of Massachusetts with over 3M members in Massachusetts and across New England. The contract expands Interpace's ThyGeNEXT and ThyraMIR thyroid assays as both covered services and now in-network services for BCBS of Massachusetts' 3M members and their families. As a result of this Agreement, members of BCBS of Massachusetts can take advantage of the benefits of ThyGeNEXT and ThyraMIR testing due to Interpace's status as an in-network provider. While terms of this Agreement are not disclosed, Interpace now benefits from a claim adjudication perspective as an in-network lab. Interpace has also successfully achieved positive medical coverage for its services through Medicare as well as other leading National and Regional health plans and is now entering into contracts to confirm such agreements.

ShowHide Related Items >><<
IDXG Interpace Biosciences
$6.55 /

-0.5 (-7.09%)

01/16/20 Oppenheimer
Interpace Biosciences price target raised to $17 from $2 at Oppenheimer
09/25/19 Oppenheimer
Oppenheimer starts Interpace at Outperform, sees 'clear path to BioPharma'
09/25/19 Oppenheimer
Interpace Diagnostics initiated with an Outperform at Oppenheimer
Hot Stocks
Interpace Biosciences announces extension of LabCorp agreement » 06:56
02/24/20
02/24
06:56
02/24/20
06:56
IDXG

Interpace Biosciences

$10.55 /

+0.34 (+3.33%)

, LH

LabCorp

$189.62 /

+0.68 (+0.36%)

Interpace Biosciences…

Interpace Biosciences (IDXG) announced that its agreement with LabCorp (LH) has been extended for an additional two years, through January 2022. Interpace and LabCorp initially entered in to their collaboration in 2016 through which LabCorp became the first national laboratory in the U.S. to offer electronic ordering and result reporting for Interpace's proprietary ThyGeNEXT and ThyraMIR tests for thyroid cancer. Terms of the agreement extension were not disclosed.

ShowHide Related Items >><<
IDXG Interpace Biosciences
$10.55 /

+0.34 (+3.33%)

01/16/20 Oppenheimer
Interpace Biosciences price target raised to $17 from $2 at Oppenheimer
09/25/19 Oppenheimer
Oppenheimer starts Interpace at Outperform, sees 'clear path to BioPharma'
09/25/19 Oppenheimer
Interpace Diagnostics initiated with an Outperform at Oppenheimer
LH LabCorp
$189.62 /

+0.68 (+0.36%)

02/13/20 Piper Sandler
LabCorp price target raised to $219 from $177 at Piper Sandler
01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
LabCorp initiated with an Overweight at Wells Fargo
12/19/19 JPMorgan
JPMorgan calls CVS top sector pick for 2020, boosts price target to $97
Hot Stocks
Interpace Biosciences CFO James Early to retire, of Fred Knechtel to succeed » 06:57
01/30/20
01/30
06:57
01/30/20
06:57
IDXG

Interpace Biosciences

$7.74 /

-0.38 (-4.68%)

Early has been working at…

Early has been working at Interpace since 2016. Previously, Knechtel held numerous CFO roles with companies that range in size from $100M-$5B in revenue.

ShowHide Related Items >><<
IDXG Interpace Biosciences
$7.74 /

-0.38 (-4.68%)

01/16/20 Oppenheimer
Interpace Biosciences price target raised to $17 from $2 at Oppenheimer
09/25/19 Oppenheimer
Oppenheimer starts Interpace at Outperform, sees 'clear path to BioPharma'
09/25/19 Oppenheimer
Interpace Diagnostics initiated with an Outperform at Oppenheimer

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.